Patents by Inventor Douglas Auld

Douglas Auld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7202050
    Abstract: A method for determining the level of kinase activity or phosphatase activity in a sample without the use of antibodies or radioactive labels is disclosed. The method employs a fluorescently-labeled phosphorylatable reporter peptide that is capable of being cleaved by a protease only when the peptide is in an unphosphorylated state. A change in fluorescence characteristics is an indication that the peptide is cleaved and, therefore, in an unphosphorylated state. Thus, the level of protease cleavage, as measured by the fluorescence change, provides a direct measure of phosphatase activity whereas the level of kinase activity is inversely proportion to the level of protease cleavage. The method is particularly well suited to high throughput screening, for example, for screening compounds which modulate kinase or phosphatase activity.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: April 10, 2007
    Assignee: Pharmacopeia Drug Discovery, Inc.
    Inventor: Douglas Auld
  • Patent number: 6942987
    Abstract: A method for determining the level of kinase activity or phosphatase activity in a sample without the use of antibodies or radioactive labels is disclosed. The method employs a fluorescently-labeled phosphorylatable reporter peptide that is capable of being cleaved by a protease only when the peptide is in an unphosphorylated state. A change in fluorescence characteristics is an indication that the peptide is cleaved and, therefore, in an unphosphorylated state. Thus, the level of protease cleavage, as measured by the fluorescence change, provides a direct measure of phosphatase activity whereas the level of kinase activity is inversely proportion to the level of protease cleavage. The method is particularly well suited to high throughput screening, for example, for screening compounds which modulate kinase or phosphatase activity.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: September 13, 2005
    Assignee: Pharmacopeia Drug Discovery, Inc.
    Inventor: Douglas Auld
  • Publication number: 20050191718
    Abstract: A method for determining the level of kinase activity or phosphatase activity in a sample without the use of antibodies or radioactive labels is disclosed. The method employs a fluorescently-labeled phosphorylatable reporter peptide that is capable of being cleaved by a protease only when the peptide is in an unphosphorylated state. A change in fluorescence characteristics is an indication that the peptide is cleaved and, therefore, in an unphosphorylated state. Thus, the level of protease cleavage, as measured by the fluorescence change, provides a direct measure of phosphatase activity whereas the level of kinase activity is inversely proportion to the level of protease cleavage. The method is particularly well suited to high throughput screening, for example, for screening compounds which modulate kinase or phosphatase activity.
    Type: Application
    Filed: April 6, 2005
    Publication date: September 1, 2005
    Applicant: Pharmacopeia Drug Discovery, Inc.
    Inventor: Douglas Auld
  • Publication number: 20050079568
    Abstract: A method for determining the level of kinase activity or phosphatase activity in a sample without the use of antibodies or radioactive labels is disclosed. The method employs a fluorescently-labeled phosphorylatable reporter peptide that is capable of being cleaved by a protease only when the peptide is in an unphosphorylated state. A change in fluorescence characteristics is an indication that the peptide is cleaved and, therefore, in an unphosphorylated state. Thus, the level of protease cleavage, as measured by the fluorescence change, provides a direct measure of phosphatase activity whereas the level of kinase activity is inversely proportion to the level of protease cleavage. The method is particularly well suited to high throughput screening, for example, for screening compounds which modulate kinase or phosphatase activity.
    Type: Application
    Filed: May 15, 2002
    Publication date: April 14, 2005
    Applicant: Pharmacopeia, Inc.
    Inventor: Douglas Auld
  • Patent number: D288339
    Type: Grant
    Filed: July 23, 1984
    Date of Patent: February 17, 1987
    Inventor: Douglas Auld
  • Patent number: D290274
    Type: Grant
    Filed: August 10, 1984
    Date of Patent: June 9, 1987
    Inventor: Douglas Auld